TY - JOUR
T1 - Longer Survival From Melanoma in Germany
T2 - A Registry-Based Time Series Study
AU - Eisemann, Nora
AU - Schumann, Laura
AU - Baltus, Hannah
AU - Labohm, Louisa
AU - Kraywinkel, Klaus
AU - Katalinic, Alexander
N1 - Publisher Copyright:
© 2024 Deutscher Arzte-Verlag GmbH. All rights reserved.
PY - 2024/1/26
Y1 - 2024/1/26
N2 - BACKGROUND: New treatment options for cutaneous melanomas with a poor prognosis have been available since 2011, including immune therapies and targeted drugs. Randomized controlled trials have demonstrated that these treatments improve survival, but no population-level studies have been available to date.METHODS: All patients in the database of the Center for Cancer Registry Data (Zentrum für Krebsregisterdaten) who had a diagnosis of melanoma (ICD10: C43) in the years 2000 to 2019 were included in the study. The relative five-year survival (5YRS) was calculated for four 5-year periods (2000-04, 2005-09, 2010-14, 2015-19). The data were standardized/stratified according to sex, age group, and UICC stage to correct for differences between regions and over time. Regression models were used to detect statistically significant secular trends.RESULTS: 301 486 individuals were included in the study. The overall 5YRS rose from 93% (2000-04) to 95% (2015-19). The 5YRS in 2015-19 was similar to or greater than that in 2000-04 for all subgroups. The largest rises in 5YRS were between 2010-14 and 2015-19, and specifically in advanced stages: for UICC stage IV tumors, the 5YRS rose from 31% to 36%. There was a significant rising trend across the four time periods (p < 0.001).CONCLUSION: The survival of melanoma patients has improved over the past 20 years. From 2010-14 to the most recent period, the largest changes were seen in advanced tumor stages. This favorable development coincided with the introduction of new therapies.
AB - BACKGROUND: New treatment options for cutaneous melanomas with a poor prognosis have been available since 2011, including immune therapies and targeted drugs. Randomized controlled trials have demonstrated that these treatments improve survival, but no population-level studies have been available to date.METHODS: All patients in the database of the Center for Cancer Registry Data (Zentrum für Krebsregisterdaten) who had a diagnosis of melanoma (ICD10: C43) in the years 2000 to 2019 were included in the study. The relative five-year survival (5YRS) was calculated for four 5-year periods (2000-04, 2005-09, 2010-14, 2015-19). The data were standardized/stratified according to sex, age group, and UICC stage to correct for differences between regions and over time. Regression models were used to detect statistically significant secular trends.RESULTS: 301 486 individuals were included in the study. The overall 5YRS rose from 93% (2000-04) to 95% (2015-19). The 5YRS in 2015-19 was similar to or greater than that in 2000-04 for all subgroups. The largest rises in 5YRS were between 2010-14 and 2015-19, and specifically in advanced stages: for UICC stage IV tumors, the 5YRS rose from 31% to 36%. There was a significant rising trend across the four time periods (p < 0.001).CONCLUSION: The survival of melanoma patients has improved over the past 20 years. From 2010-14 to the most recent period, the largest changes were seen in advanced tumor stages. This favorable development coincided with the introduction of new therapies.
UR - https://www.mendeley.com/catalogue/0ec9b5ac-ce47-3050-9f62-ff72e90ca4bc/
UR - http://www.scopus.com/inward/record.url?scp=85186927607&partnerID=8YFLogxK
U2 - 10.3238/arztebl.m2023.0242
DO - 10.3238/arztebl.m2023.0242
M3 - Journal articles
C2 - 38054977
SN - 1866-0452
VL - 121
SP - 45
EP - 51
JO - Deutsches Arzteblatt International
JF - Deutsches Arzteblatt International
IS - 2
ER -
